Erectile dysfunction is a common disease that affects approximately 10% of adult men in the world.
Since 1983, several products for the treatment of erectile dysfunction such as injection formulations of phenoxybenzamin, papaverin hydrochloride, phentolamin mesylate and prostaglandin E 1 , intended to be injected into the corpus cavernosum were introduced. However, the intracorporeal injection of these products has occasionally been accompanied by the side effects such as pain, priapism, penile hematomas and fibrosis. For these reasons, up to 50% of erectile dysfunction patients using intracavernous injection therapy eventually discontinue the treatment. 2, [4] [5] [6] Up to now, prostaglandin E 1 (PGE 1 ) has been known as one of the most potent compounds used as a single-dose pharmacotherapy for erectile dysfunction 7) generally administered by intracavernosal injection (e.g., Caverject ® , Pfizer). PGE 1 increases the intracellular concentration of 3Ј,5Ј-cyclic adenosine monophosphate (cAMP) by activation of specific membrane receptors that interact with stimulatory guanine nucleotide proteins to trigger adenylate cyclase and elevate intracellular cAMP concentration. 8) Increasing the intracellular cAMP concentration induces the relaxation of arterial and trabecular smooth muscle in the corpus cavernosum and thereby causes penile erection. 7) A non-invasive intraurethral PGE 1 suppository (MUSE ® , Vivus Inc.) has been introduced as a more convenient and safer formulation compared to the injection type of PGE 1 . 1) However, intraurethral suppository formulation may cause some discomforts including feeling of foreign body and pain mainly exhibited by bulky insertion device. 9, 10) For this reason, we attempted to develop a novel liquid type intraurethral PGE 1 delivery formulation using a self-microemulsifying drug delivery system (i.e. SMEDDS). The liquid type intraurethral formulation has some pharmaceutical significances from the viewpoint of patients' compliance as follows; i) non-invasive drug delivery is possible, ii) administration is easier into the urethra than pellet type solid suppository products, and iii) less pain is expected.
SMEDDS can be defined as an isotropic multi-component drug delivery system composed of surfactant, co-surfactant and oil, which in some cases transforms to viscous solution with contacting moisture and spontaneously forms microemulsion in the presence of excessive water. [11] [12] [13] Traditionally, SMEDDS formulation has been used to increase dissolution rate or bioavailability of water insoluble drugs. [14] [15] [16] The liquid type intraurethral formulation presented in this paper is practically a precursor mixture for forming a microemulsion. Thus, it is expected that the present SMEDDS formulation can be administered into the urethra by simple input procedure, reside in the urethra as a viscous liquid by taking up an aqueous media, and easily eliminated by transforming to free flowing microemulsion upon urination.
In this study, we first report the applicability of SMEDDS as an intraurethral drug delivery system by evaluating the phase behavior, together with viscosity changes and selfemulsification efficiency. With these, irritancy, long term stability test was examined and pharmacodynamic effect of PGE 1 intraurethral SMEDDS formulation was tested with wild male feline model. , and the mixture was stirred for 1 h and left for 1 d until equilibrium. After equilibrium was reached, the samples were assessed by visual observation. Optically clear and non-birefringent solution was termed as transparent liquid phase (T), clear systems which did not show a change in meniscus after tilting to an angle of 90°were classified as gel phase (G) and a transparent and blue fluid was termed as microemulsion (M). Finally, gray turbid solution and milky emulsion were termed as turbid liquid (TL) and emulsion (E), respectively. During the construction of phase diagram, the ratio of surfactant to co-surfactant (k m ) was varied to examine the impact of surfactant/ co-surfactant ratio on the phase behavior.
MATERIALS AND METHODS

Materials
Measurement of Viscosity To estimate the urethral retention property of PGE 1 intraurethral SMEDDS formulation, viscosity was measured with a viscometer (Haake RV100, Germany) as a function of water content at 37°C.
Evaluation of Self-Microemulsification Degree of selfmicroemulsification was determined based on the method reported by Khoo et al. 16) Briefly, 1 ml of intraurethral SMEDDS formulation was added to 200 ml of 37°C distilled water and a paddle was gently rotated at 60 rpm. The selfemulsification property was assessed with parameters of emulsification time, appearances and particle size of final emulsion. The evaluation criteria for emulsification time and appearance were summarized in Table 1 .
Measurement of Droplet Size Mean droplet size was determined using a dynamic light scattering system (PCS4700, Malvern Co., U.K.) at conditions of scattering angle of 90°and 12000 counts per second.
Mucous Irritation Test Draize test is as well established method to ensure the safety of consumer products and became a governmentally endorsed method to evaluate the safety of materials meant for use in or around the eyes. 18) To predict the irritancy of PGE 1 intraurethral SMEDDS formulation at mucous of urethra and the safety of formulation, we performed Draize test with rabbits as an alternative way to predict the irritancy of SMEDDS within the human urethra. After confirming that the rabbits' eyes were normal, 0.1 ml of intraurethral formulation was administered into the conjunctival sac of one side eye of 6 rabbits weighting 2.0 to 3.0 kg. As parameters for irritation, the opacity and the affected area of cornea, congestion and swelling of iris, redness of palpebral conjunctivae were observed and scored for 7 d after treatment following the guideline of Draize test. 19) Long-Term Stability of PGE 1 The composition of intraurethral SMEDDS formulation used for long-term stability test was Cremophor ELP ® : Ethanol : Labrafac CC ® ϭ 5 : 2 : 3 and the PGE 1 concentration was 1 mg/ml. This formulation was selected from the phase diagram study, observation of viscosity profiles and self-microemulsifying test. To prepare the intraurethral SMEDDS formulation, PGE 1 was dissolved in ethanol solution first and the PGE 1 ethanol solution was added to the mixture of Cremophor ELP ® and Labrafac CC ® .
The intraurethral SMEDDS formulation was placed into light-shielded vials, and they were stored in an incubator maintained at a constant humidity of 75%, relative humidity (RH) and various temperatures from 4 to 40°C. At appropriate time intervals, the remaining amount of PGE 1 was analyzed with HPLC.
Analysis Condition of PGE 1 Reverse phase Capcell Pak C 18 (4.6ϫ150 mm, particle size 5 mm) column was used to analyze remained amount of PGE 1 . The composition of mobile phase was acetonitrile : 0.02 M phosphate buffer (pH 4.9)ϭ40 : 60 (v/v) and the flow rate was 1.0 ml/min. Detection wavelength and injection volume were 200 nm and 20 ml, respectively.
In Vivo Pharmacodynamic Study Matured male cats (Samyook Laboratory Animals, Korea) weighed 2.5 to 3.0 kg were used. The cats were anesthetized with pentobarbital (40 mg/kg) and outer skin of the penis was excised with a scalpel. The SMEDDS was administered with a disposable syringe. Briefly, the syringe was filled with the SMEDDS and the polyethylene tube (i.d. 0.1 mm, o.d. 1.2 mm) was connected to the end of the syringe to inject SMEDDS formulations into the urethra of the cats. After intraurethral application of 50 ml of the SMEDDS formulation (1 mg/ml PGE 1 ), intracavernosal pressure (ICP, mmHg) and duration of erection were measured with Statham pressure transducer (Model # P23 ID) connected to Grass Model 7 polygraph (Grass Instrument Co., Quincy, MA, U.S.A.) and penile length (mm) was also measured with a ruler.
Statistical Analysis Statistical analysis of data sets for each group of measurements was performed using Student's t test. Level of significance was taken as pϽ0.05 except where stated otherwise.
RESULTS AND DISCUSSION
As shown in Fig. 1 , the areas of gel and microemulsion became expanded as the k m value increased. When k m was 1.5, gel and microemulsion areas were located between oil/(surfactant and co-surfactant) ratio of 0.1 to 0.2. When k m values were 2.0 and 2.5, the area of gel and microemulsion was broaden and they were found between oil/(surfactant and cosurfactant) ratio of 0.1 to 0.25 and 0.1 to 0.4, respectively. To estimate the mode of intraurethral SMEDDS formulation within urethra, viscosity profile of selected compositions (Table 2 ) which simultaneously pass through the center of gel and microemulsion area was observed with the change of water contents. The viscosity was increased gently until water content reached to approximately 35% of total mass (Fig. 2, insert) and it showed steep increase until water content reached to 40% of total mass, and then the viscosity was decreased rapidly (Fig. 2) . Based on the results from viscosity measurement, the current SMEDDS formulation devoid of water can easily be input due to its low viscosity. Once being input, the SMEDDS formulation is anticipated to take up water and thereby form highly viscous gel-like liquid, almost certainly leading to an increase in the urethral residence time. However, when it takes up an additional aqueous media, its viscosity would dramatically be decreased, by which the formulation can be washed out easily by urination. We evaluated the self-emulsification properties of the PGE 1 intraurethral SMEDDS formulation by observing optical appearances and particle size to confirm whether the intraurethral SMEDDS formulation could readily be transformed to microemulsion. When 1 ml of the intraurethral SMEDDS formulation was added to 200 ml of warm distilled water (37°C), it was easily self-microemulsified only by gentle stirring. All formulations tested were transformed to microemulsions having very low viscosity and the particle size of the microemulsions produced was under 200 nm (Table 3) .
Generally, anhydrous SMEDDS becomes viscous system upon the addition of water. When it uptakes water, initially w/o micelles would be formed and they become enlarged. The micelles grow to a cylindrical or worm-like structure, which tends to give rise to viscous system. 20) In one report about topical delivery of b-blockers using anhydrous SMEDDS composed of surfactant-isopropyl myristate mixture, bupranolol was applied to New Zealand albino rabbits. In their study, the pharmacological activity was improved when water was partitioned into the system from skin, where they discussed this was due to the enhanced diffusion pressure induced by the enhanced thermodynamic activity of bupranolol within the system. 21, 22) In other study, when the anhydrous pseudo-binary system composed of lecithin and fatty acid ester oil containing indomethacin uptake water, the anhydrous SMEDDS formed gel system and the skin perme- 670 Vol. 31, No. 4 ation of indemethacin was increased by the same mechanism. 23) From the phase study and the measurement of viscosity profile, the present PGE 1 SMEDDS formulation for intraurethral delivery of PGE 1 became viscous system when it contacted with water. Although the onset time was delayed, the vasodilatory effect was maintained for 2 h (Fig. 4) . This may be due to the enhanced residence time of PGE 1 onto the urethral mucosa.
Although there have been criticism relating to the ethical and scientific aspects of Draize test, this test method have been known as a standardized toxicological method for the study of irritation and toxicity to mucosal tissues for some decade. 24, 25) In the present Draize test, the control SMEDDS was proven to be safe as a PGE 1 carrier applicable to human mucosa (Table 4 ). In case of PGE 1 -contained test formulation, no significant changes indicating eye irritation were observed in the cornea. Only some congestion of cornea was observed at the 1 h and the affected corneal area was disappeared after 6 h and there was no swelling of iris was found. The conjunctivae showed some redness at the initial of test however it disappeared after 6 h. Thus, we could predict that the present intraurethral PGE 1 SMEDDS formulation would be safe enough to be applied into the human urethra.
It was reported that PGE 1 is very unstable under aqueous conditions due to the degradation of PGE 1 to prostaglandin A 1 (PGA 1 ), which is accelerated by acidic and basic environment and PGA 1 is further isomerized to prostaglandin B 1 (PGB 1 ). 26) To ensure the stability of PGE 1 in the SMEDDS formulation, we performed stability test at 4, 20, 30 and 40°C for over one year. As shown in Fig. 3 , the semi-log degradation pattern of PGE 1 followed a first-order reaction, PGE 1 was estimated to be stable over one year at the shelf storage temperature of 4°C. The arrhenius plot, depicted with the degradation coefficients at each temperature, showed a good correlation with R 2 of 0.9977. There have been several reports that intracavernous pressures (ICP, mmHg) could be measured with cat model to investigate the effect of vasoactive agents on penile erectile responses. 27, 28) Figure 4 shows the result of ICP measurements after input of PGE 1 intraurethral SMEDDS formulation into the cat's urethra. The pharmacological activity of the intraurethral SMEDDS formulation was compared with PGE 1 ethanol solution of 1 and 2 mg/ml, which were injected onto the right and left side of corpus cavernosum of cats. The initial ICP value obtained with intraurethral SMEDDS formulation was lower than that of intracavernosal injection controls (i.e. PGE 1 ethanol solutions) but it increased up to 100 mmHg steadily and maintained for 30 min. As shown in Fig. 5 , the penile length (mm) erected by the intraurethral SMEDDS formulation was similar to that of PGE 1 ethanol However, the duration of erectile response (min) of intraurethral SMEDDS formulation was significantly more extended than that of intracavernosal injections (pϽ0.05). Although 25 to 50 times amount of PGE 1 showed similar pharmacological effects exhibited by 1 or 2 mg of PGE 1 intracavernosal injections, the intraurethral PGE 1 delivery is still attractive method in terms of patient compliances as shown by the commercialized urethral suppository, MUSE ® (PGE 1 1 mg, Vivus Inc.). Thus, we could expect that the present SMEDDS formulation become a good alternative medication against the invasive injection product by providing enhanced patient compliances.
CONCLUSION
To characterize the present novel PGE 1 intraurethral solution, pseudo-ternary phase diagram was constructed. The change of viscosity by the function of water contents and evaluation of self-microemulsification with 37°C water were observed. The addition of water to SMEDDS up to approximately 35% of total mass resulted in an increase of viscosity that may help prolong the residence time of the formulation within the urethra. The maximum viscosity was achieved at the water content of 40% and the viscosity was rapidly decreased, and free flowing microemulsion was produced when water contents exceeds 40%. The Draize test showed that the intraurethral SMEDDS formulation would be safe to urethral mucosa. The PGE 1 intraurethral SMEDDS formulation caused a similar pharmacological response to that shown by PGE 1 intracavernosal injection in terms of ICP and penile length increment, and it was superior to the controls in erection sustaining time. Moreover, PGE 1 was stable for more than one year at the shelf temperature of 4°C. Conclusively, the present intraurethral PGE 1 solution employing SMEDDS was identified as a promising formulation for erectile dysfunction treatment. 
